OTCMKTS:ASNB EKIMAS (ASNB) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free ASNB Stock Alerts $0.61 0.00 (0.00%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$0.61▼$0.6150-Day Range$0.45▼$0.6152-Week Range$0.55▼$1.75VolumeN/AAverage Volume3,162 shsMarket Capitalization$3.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsStock AnalysisChartFinancialsSEC Filings Get EKIMAS alerts: Email Address Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic About EKIMASEKIMAS Corp. engages in the development of polymer materials, which provide characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. The firm's products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Las Vegas, NV.Read More ASNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASNB Stock News HeadlinesMarch 8, 2023 | finance.yahoo.comEKIMAS CORPORATION COMPLETES THE EXERCISE OF WARRANTSMarch 1, 2023 | finance.yahoo.comNORDICUS PARTNERS A/S COMPLETES REVERSE ACQUISITION TRANSACTION WITH EKIMAS CORPORTIONApril 18, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.September 14, 2022 | reuters.comASNB.PK - Ekimas Corp | Stock Price & Latest News | ReutersSeptember 12, 2022 | finance.yahoo.comUpdated EKIMAS Corporation Announces Special Cash DistributionSeptember 10, 2022 | yahoo.comWhat does ‘WYLL’ mean on TikTok and Snapchat?August 28, 2022 | finance.yahoo.comEKIMAS Corporation (ASNB)See More Headlines Receive ASNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EKIMAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/16/2014Today4/18/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:ASNB Previous SymbolAMEX:ASB CUSIPN/A CIK1011060 Webwww.advbiomaterials.com Phone(424) 256-8560Fax978-657-0074Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-7,902.31% Return on Assets-5,274.01% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book20.33Miscellaneous Outstanding Shares5,799,000Free Float5,347,000Market Cap$3.54 million OptionableNot Optionable Beta0.37 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesHenrik RoufChief Executive OfficerBennett J. YankowitzChief Financial Officer & DirectorKey CompetitorsAethlon MedicalNASDAQ:AEMDG Medical InnovationsNASDAQ:GMVDFCatheter PrecisionNYSEAMERICAN:VTAKUnited American HealthcareOTCMKTS:UAHCTenon MedicalNASDAQ:TNONView All Competitors ASNB Stock Analysis - Frequently Asked Questions How have ASNB shares performed in 2024? EKIMAS's stock was trading at $0.62 at the beginning of 2024. Since then, ASNB shares have decreased by 1.6% and is now trading at $0.61. View the best growth stocks for 2024 here. How were EKIMAS's earnings last quarter? EKIMAS Co. (OTCMKTS:ASNB) announced its earnings results on Thursday, October, 16th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.29 by $0.02. During the same quarter last year, the company posted $0.27 earnings per share. What other stocks do shareholders of EKIMAS own? Based on aggregate information from My MarketBeat watchlists, some companies that other EKIMAS investors own include NVIDIA (NVDA), Associated Banc (ASB), PermRock Royalty Trust (PRT), CytoDyn (CYDY), FuelCell Energy (FCEL), Interpace Biosciences (IDXG), Sphere 3D (ANY), AVEO Pharmaceuticals (AVEO), Boeing (BA) and Bank of America (BAC). How do I buy shares of EKIMAS? Shares of ASNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ASNB) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressBiden’s $374B Giveaway Into This SectorDTIA.I. Pioneer Issues Urgent Warning to AmericansTradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EKIMAS Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.